Completed
PHASE2
INTERVENTIONAL
NCT01839149
TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.
Interventions
Name:
TI-001
Type:
DRUG
Description:
TI-001 is intranasal oxytocin
Name:
Placebo
Type:
DRUG
Description:
Primary Outcomes
Measure:
Mean change of migraine days
TimeFrame:
Baseline and 28 days of treatment
Description:
Baseline is the 28-day screening period before study drug administration
Trial Information
NCT ID
NCT01839149
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Trigemina, Inc
Last Updated
December 15, 2025